Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 176,855,692 | 138,798,417 | 150,881,176 | 139,394,431 | 155,691,017 | 761,620,733 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 176,855,692 | 138,798,417 | 150,881,176 | 139,394,431 | 155,691,017 | 761,620,733 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 761,620,733 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 176,855,692 | 138,798,417 | 150,881,176 | 139,394,431 | 155,691,017 | 761,620,733 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 6,807,160 | 9,621,065 | 6,721,516 | 10,050,004 | 14,786,344 | 47,986,089 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 1,945 | 4,857 | 2,864 | 31,986 | 64,152 | 105,804 |
| 11 | Total support. Add lines 7 through 10 | 809,773,531 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2024 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2024 |
(iii) Distributable Amount for 2024 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2024 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2024 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2024: | ||||
| a From 2019....... | ||||
| b From 2020....... | ||||
| c From 2021....... | ||||
| d From 2022....... | ||||
| e From 2023....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2024 distributable amount | ||||
|
i
Carryover from 2019 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2024 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2024 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2025. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2020..... | ||||
| b Excess from 2021..... | ||||
| c Excess from 2022..... | ||||
| d Excess from 2023..... | ||||
| e Excess from 2024..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| Schedule A, Part II, Line 10 Other Income | DESCRIPTION - ROYALTIES, COLUMN A - 993.0, COLUMN B - 2851.0, COLUMN C - 1781.0, COLUMN D - 1183.0, COLUMN E - 1213.0, COLUMN F - 8021.0; DESCRIPTION - REVENUE SHARING-HOST VEHICLE CHARGING STATION, COLUMN A - 952.0, COLUMN B - 2006.0, COLUMN C - 1083.0, COLUMN D - 1997.0, COLUMN E - 2388.0, COLUMN F - 8426.0; DESCRIPTION - AR RECHARGE ALLOWANCE, COLUMN A - 0.0, COLUMN B - 0.0, COLUMN C - 0.0, COLUMN D - 28806.0, COLUMN E - 60282.0, COLUMN F - 89088.0; DESCRIPTION - OTHER, COLUMN A - 0.0, COLUMN B - 0.0, COLUMN C - 0.0, COLUMN D - 0.0, COLUMN E - 269.0, COLUMN F - 269.0; |
| Software ID: | 24020961 |
| Software Version: | 2024v5.1 |
| Return Reference | Explanation |
|---|---|
| Form 990, Part VI, Line 1a Delegate broad authority to a committee | THE EXECUTIVE COMMITTEE SHALL ADVISE AND AID THE OFFICERS OF THE CORPORATION IN ALL MATTERS CONCERNING ITS INTERESTS, INCLUDING WITHOUT LIMITATION ALL MATTERS RELATING TO COMPENSATION AND BENEFITS, AND SHALL POSSESS AND MAY EXERCISE, DURING THE INTERVALS BETWEEN THE MEETINGS OF THE BOARD OF TRUSTEES, ALL THE POWERS AND AUTHORITY OF THE BOARD OF TRUSTEES IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE CORPORATION, INCLUDING THE POWER TO AUTHORIZE THE CORPORATE SEAL TO BE AFFIXED TO ANY AND ALL DOCUMENTS WHICH MAY REQUIRE THE SAME TO BE AFFIXED THERETO, INSOFAR AS SUCH SEEMS TO THE EXECUTIVE COMMITTEE FOR THE BEST INTERESTS OF THE CORPORATION, IN ALL CASES IN WHICH SPECIFIC DIRECTIONS SHALL NOT HAVE BEEN GIVEN BY THE BOARD OF TRUSTEES, EXCEPT THAT THE EXECUTIVE COMMITTEE SHALL HAVE NO POWER TO ADOPT, AMEND, OR REPEAL THE BY-LAWS. |
| Form 990, Part VI, Line 6 Classes of members or stockholders | MEMBERSHIP OF THE CORPORATION CONSISTS OF THE PERSONS ELECTED TO THE BOARD OF TRUSTEES AND THREE MEMBERS FROM AMONG THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS CHOSEN AND ELECTED ANNUALLY BY THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS. |
| Form 990, Part VI, Line 7a Members or stockholders electing members of governing body | THE MEMBERS OF THE CORPORATION ELECT THE TRUSTEES. |
| Form 990, Part VI, Line 7b Decisions requiring approval by members or stockholders | THE MEMBERS OF THE CORPORATION MAY ALTER, AMEND, OR REPEAL THE BY-LAWS BY VOTE. |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | THE FORM 990 IS PREPARED BY THE INSTITUTE, INTERNALLY REVIEWED BY THE CHIEF FINANCIAL OFFICER AND EXTERNALLY REVIEWED BY THE TAX DEPARTMENT OF A PUBLIC ACCOUNTING FIRM. PRIOR TO ELECTRONIC FILING, A COPY OF THIS FORM 990 IS PROVIDED TO AND DISCUSSED IN THE EXECUTIVE SESSION OF THE BOARD OF TRUSTEES. |
| Form 990, Part VI, Line 12c Conflict of interest policy | ANNUALLY, THE CONFLICT OF INTEREST DISCLOSURE STATEMENT IS SENT OUT FOR COMPLETION BY THE MEMBERS OF THE BOARD OF TRUSTEES, SENIOR MEMBERS OF ADMINISTRATION AND RESEARCHERS. THE DESIGNATED OFFICIAL FOR EACH GROUP REVIEWS THE COMPLETED FORMS AND BRINGS ANY POTENTIAL CONFLICT OF INTEREST TO THE RESPECTIVE COMMITTEES FOR REVIEW. UPON DETERMINATION THAT A CONFLICT OF INTEREST EXISTS, THE FOLLOWING CONDITIONS OR RESTRICTIONS MAY BE IMPOSED: A. MONITORING OF ACTIVITIES GENERATING THE CONFLICT BY ANOTHER MEMBER; B. DISQUALIFICATION FROM PARTICIPATION IN THE ACTIVITIES GIVING RISE TO THE CONFLICT; C. MODIFICATION OF RESPONSIBILITIES TO AVOID CONFLICTS; D. PUBLIC DISCLOSURE OR DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS; E. MODIFICATION OF THE RESEARCH PLAN OR REMOVAL OF THE AFFECTED RESEARCHER FROM THE RESEARCH; F. SEVERANCE OF RELATIONSHIP THAT CREATES ACTUAL OR POTENTIAL CONFLICTS; G. TERMINATION OF EMPLOYMENT. |
| Form 990, Part VI, Line 15a Process to establish compensation of top management official | A COMPREHENSIVE MARKET ASSESSMENT WAS COMPLETED IN APRIL 2024, BASED ON COMPENSATION DATA FROM A SELECTED PEER GROUP FOR SALK PRESIDENT AND EXECUTIVE LEADERSHIP ROLES. THIS ASSESSMENT WAS PROVIDED TO SALK'S BOARD CHAIR, CO-CHAIR, CHAIR OF THE PEOPLE & CULTURE COMMITTEE, AND TO SALK'S PRESIDENT. SALK'S PRESIDENT AND THE INSTITUTE'S VICE-PRESIDENT PEOPLE & CULTURE DISCUSSED THE PERFORMANCE OF VICE-PRESIDENT-LEVEL EXECUTIVES AT A MEETING ON MARCH 28, 2025; THE VICE-PRESIDENT PEOPLE & CULTURE WAS NOT PRESENT FOR DISCUSSION ABOUT HER PERFORMANCE. AFTER THIS MEETING, A SEPARATE DISCUSSION ABOUT THE COMPENSATION OF THE INSTITUTE PRESIDENT, RECOMMENDED CHANGES WERE PRESENTED TO AND APPROVED BY THE SALK BOARD OF TRUSTEES AT THE EXECUTIVE SESSION OF THE APRIL 4, 2025 BOARD OF TRUSTEES MEETING. |
| Form 990, Part VI, Line 15b Process to establish compensation of other employees | A COMPREHENSIVE MARKET ASSESSMENT WAS COMPLETED IN APRIL 2024, BASED ON COMPENSATION DATA FROM A SELECTED PEER GROUP FOR SALK PRESIDENT AND EXECUTIVE LEADERSHIP ROLES. THIS ASSESSMENT WAS PROVIDED TO SALK'S BOARD CHAIR, CO-CHAIR, CHAIR OF THE PEOPLE & CULTURE COMMITTEE, AND TO SALK'S PRESIDENT. SALK'S PRESIDENT AND THE INSTITUTE'S VICE-PRESIDENT PEOPLE & CULTURE DISCUSSED THE PERFORMANCE OF VICE-PRESIDENT-LEVEL EXECUTIVES AT A MEETING ON MARCH 28, 2025; THE VICE-PRESIDENT PEOPLE & CULTURE WAS NOT PRESENT FOR DISCUSSION ABOUT HER PERFORMANCE. AFTER THIS MEETING, A SEPARATE DISCUSSION ABOUT THE COMPENSATION OF THE INSTITUTE PRESIDENT, RECOMMENDED CHANGES WERE PRESENTED TO AND APPROVED BY THE SALK BOARD OF TRUSTEES AT THE EXECUTIVE SESSION OF THE APRIL 4, 2025 BOARD OF TRUSTEES MEETING. |
| Form 990, Part VI, Line 19 Required documents available to the public | UPON REQUEST, THE OFFICE OF THE CHIEF FINANCIAL OFFICER MAKES AVAILABLE TO THE PUBLIC THE INSTITUTE'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY. FINANCIAL STATEMENTS ARE AVAILABLE ON THE SALK WEBSITE. |
| Form 990, Part VII, Section A DIRECTORS COMPENSATION | THE FOLLOWING INDIVIDUALS WERE COMPENSATED FOR THE FOLLOWING SERVICES AND NOT PAID AS TRUSTEES: GERALD JOYCE, PH.D. - PRESIDENT/PROFESSOR; REUBEN SHAW, PH.D. - PROFESSOR; JANELLE AYRES, PH.D. - PROFESSOR; WOLFGANG BUSCH, PH.D. - PROFESSOR; CHRISTIAN METALLO, PH.D. - PROFESSOR. |
| Form 990, Part VIII, Line 11d Other Miscellaneous Revenue | OTHER REVENUE - Total Revenue: 269, Related or Exempt Function Revenue: , Unrelated Business Revenue: , Revenue Excluded from Tax Under Sections 512, 513, or 514: 269; |
| Form 990, Part XI, Line 9 Other changes in net assets or fund balances | POSTRETIREMENT BENEFIT CHANGES OTHER THAN NET PERIODIC BENEFIT COST - 398627; CHANGE IN VALUE OF DEFERRED GIFTS - 186702; ROUNDING - -47; Total - 585282; |
| FORM 990, PART III, LINE 4A CONTINUED | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES IS A WORLD-RENOWED, INDEPENDENT RESEARCH INSTITUTE DEDICATED TO ADVANCING OUR UNDERSTANDING OF LIFE SCIENCES AND IMPROVING HUMAN HEALTH. ITS PROGRAMS BRING TOGETHER LEADING SCIENTISTS ACROSS DISCIPLINES TO EXPLORE FUNDAMENTAL QUESTIONS IN BIOLOGY, FROM THE MOLECULAR MECHANISMS OF DISEASE TO THE COMPLEXITIES OF THE BRAIN AND THE IMPACT OF CLIMATE CHANGE ON LIVING SYSTEMS. THROUGH COLLABORATIVE, CURIOSITY-DRIVEN RESEARCH AND INNOVATIVE TECHNOLOGY, SALK'S PROGRAMS AIM TO TRANSLATE SCIENTIFIC DISCOVERIES INTO REAL-WORLD SOLUTIONS THAT BENEFIT SOCIETY. BELOW ARE HIGHLIGHTED SCIENTIFIC ACHIEVEMENTS DURING JULY 2024 THROUGH JUNE 2025. STUDY REVEALS KEY GENE PROTECTING PLANTS FROM HARMFUL METALS IN SOIL - THE EXCESSIVE USE OF MANURE AND SEWAGE SLUDGE CAN INCREASE HEAVY METAL CONCENTRATIONS IN AGRICULTURAL LAND WHERE VITAL CROPS ARE GROWN. ONE OF THESE HEAVY METALS IS ZINC, A MICRONUTRIENT NECESSARY FOR PLANT AND ANIMAL HEALTH. IN EXCESS, HOWEVER, ZINC CAN BE EXTREMELY DAMAGING TO SENSITIVE PLANT SPECIES. SALK RESEARCHERS IDENTIFIED A GENE, CALLED TRICHOME BIREFRINGENCE OR TBR, THAT HELPS PLANTS MANAGE EXCESS ZINC BY TRAPPING IT IN THEIR ROOT CELL WALLS. SCIENTISTS AND FARMERS CAN NOW USE THIS INFORMATION TO DEVELOP AND GROW CROPS THAT ARE MORE RESILIENT TO SOIL CONTAMINATION. ENHANCING PLANT RESILIENCE IN THIS WAY IS A MAJOR GOAL OF SALK'S HARNESSING PLANTS INITIATIVE. THE STUDY WAS LED BY WOLFGANG BUSCH, PHD, AND PUBLISHED IN NATURE COMMUNICATIONS ON JULY 11, 2024. NEW TOOLS REVEAL NEUROPEPTIDES, NOT FAST NEUROTRANSMITTERS, ENCODE DANGER IN THE BRAIN - IN THE SPLIT SECOND THAT YOU ACCIDENTALLY TOUCH THE HOT HANDLE OF A CAST IRON SKILLET, PAIN AND A SENSE OF DANGER RUSH IN. RESEARCHERS ASSUMED THIS PROCESS MUST BE MEDIATED BY FAST-ACTING NEUROTRANSMITTERS, BUT SALK RESEARCHERS CREATED TWO NEW TOOLS TO STUDY THE EMOTIONAL FEAR RESPONSE CIRCUIT IN LIVE MICE FOR THE FIRST TIME. THEY FOUND THAT LARGER, SLOWER MOLECULES CALLED NEUROPEPTIDES ARE THE MAIN MESSENGERS IN THIS CIRCUIT-AND MORE THAN ONE NEUROPEPTIDE IS INVOLVED. THEIR FINDINGS MAY EXPLAIN WHY EXISTING MEDICATIONS THAT TARGET ONLY ONE NEUROPEPTIDE ARE OFTEN INEFFECTIVE AND COULD INSPIRE THE DEVELOPMENT OF NEW TREATMENTS FOR FEAR-RELATED CONDITIONS LIKE ANXIETY AND PTSD. THE STUDY WAS LED BY SUNG HAN, PHD, AND PUBLISHED IN CELL ON JULY 22, 2024. FUEL LEVEL LOW! ENERGY DEFICITS HARM ATHLETES' HEALTH, NEW RESEARCH TOOL REVEALS HOW - RELATIVE ENERGY DEFICIENCY IN SPORT, OR REDS, IS ESTIMATED TO AFFECT MORE THAN 40% OF PROFESSIONAL ATHLETES-AND THE RATE COULD BE EVEN HIGHER IN RECREATIONAL ATHLETES AND EXERCISERS. ATHLETES DEVELOP REDS BY CONSISTENTLY EXPENDING MORE ENERGY THAN THEY TAKE IN. OVER TIME, THIS ENERGY DEFICIT CAN LEAD TO HORMONAL AND REPRODUCTIVE ISSUES, INSOMNIA AND FATIGUE, BONE WEAKNESS AND INJURY, AND A HIGHER RISK OF ANXIETY AND DEPRESSION. SALK SCIENTISTS CREATED A LANDMARK MOUSE MODEL OF REDS, WITH WHICH THEY FOUND THAT REDS AFFECTS ORGAN SIZE AND GENE EXPRESSION PATTERNS ACROSS THE ENTIRE BODY. WHAT'S MORE, THE SYNDROME APPEARS TO IMPACT MALE AND FEMALE MICE DIFFERENTLY, IMPACTING KIDNEY HEALTH THE MOST IN MALES AND REPRODUCTIVE HEALTH AND MUSCLE MASS IN FEMALES. THIS WORK COULD IMPROVE REDS DIAGNOSIS AND REVEAL MOLECULAR TARGETS FOR FUTURE THERAPEUTICS TO HALT, REVERSE, OR PREVENT THE SYNDROME. THE STUDY WAS LED BY SATCHIDANANDA PANDA, PHD, AND PUBLISHED IN CELL METABOLISM ON SEPTEMBER 3, 2024. ONE IN THREE AMERICANS HAS A DYSFUNCTIONAL METABOLISM, BUT INTERMITTENT FASTING COULD HELP - MORE THAN ONE-THIRD OF ADULTS IN THE UNITED STATES HAVE METABOLIC SYNDROME, A CLUSTER OF CONDITIONS THAT SIGNIFICANTLY RAISE A PERSON'S RISK OF HEART DISEASE, STROKE, AND TYPE 2 DIABETES. THESE CONDITIONS INCLUDE HIGH BLOOD PRESSURE, ELEVATED BLOOD SUGAR, EXCESS ABDOMINAL FAT, AND ABNORMAL CHOLESTEROL LEVELS. IN A NEW CLINICAL TRIAL, RESEARCHERS AT SALK AND UC SAN DIEGO FOUND THAT TIME-RESTRICTED EATING-ALSO KNOWN AS INTERMITTENT FASTING-COULD OFFER SIGNIFICANT HEALTH BENEFITS TO ADULTS WITH METABOLIC SYNDROME. COMPARED TO OTHER PRESCRIBED LIFESTYLE CHANGES, TIME-RESTRICTED EATING COULD OFFER A MORE PRACTICAL INTERVENTION ACCESSIBLE TO A WIDER RANGE OF PATIENTS. THE STUDY WAS LED BY SATCHIDANANDA PANDA, PHD, AND PUBLISHED IN ANNALS OF INTERNAL MEDICINE ON OCTOBER 1, 2024. NEW BRAIN-MAPPING TOOL MAY BE THE "START" OF NEXT-GENERATION THERAPEUTICS - WHEN REPAIRING A CAR, IT'S IMPORTANT TO UNDERSTAND ITS BASIC BLUEPRINT AND HOW ALL THE PARTS CONNECT. TREATING BRAIN DISORDERS IS NO DIFFERENT, EXCEPT THAT SCIENTISTS ARE STILL MISSING KEY DETAILS OF THE BRAIN'S WIRING DIAGRAM. TO ADDRESS THIS, SALK RESEARCHERS DEVELOPED A NEW BRAIN-MAPPING TECHNOLOGY CALLED START. THE CUTTING-EDGE TOOL ALLOWS NEUROSCIENTISTS TO TRACE THE CONNECTIVITY BETWEEN DIFFERENT TYPES OF BRAIN CELLS WITH UNPRECEDENTED RESOLUTION. USING THIS TECHNIQUE, THE RESEARCHERS BECAME THE FIRST TO RESOLVE CORTICAL CONNECTIVITY AT THE RESOLUTION OF TRANSCRIPTOMIC CELL TYPES. THE DISCOVERIES MADE WITH START WILL HELP RESEARCHERS DESIGN NEW THERAPEUTICS THAT CAN TARGET CERTAIN NEURONS AND BRAIN CIRCUITS WITH GREATER SPECIFICITY AND EFFICACY, AND WITH FEWER SIDE EFFECTS THAN CURRENT PHARMACOLOGICAL APPROACHES. THE STUDY WAS LED BY EDWARD CALLAWAY, PHD, AND PUBLISHED IN IN NEURON ON SEPTEMBER 30, 2024. SCIENTISTS CREATE FIRST MAP OF DNA MODIFICATION IN THE DEVELOPING HUMAN BRAIN - A SALK, UC LOS ANGELES, UC SAN FRANCISCO, UC SAN DIEGO, AND SEOUL NATIONAL UNIVERSITY TEAM CREATED THE FIRST MAP OF DNA MODIFICATION IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX-TWO REGIONS OF THE BRAIN CRITICAL TO LEARNING, MEMORY, AND EMOTIONAL REGULATION, AND ALSO FREQUENTLY INVOLVED IN DISORDERS LIKE AUTISM SPECTRUM AND SCHIZOPHRENIA. THE STUDY PROVIDES AN UNPRECEDENTED LOOK AT HOW GENE REGULATION EVOLVES DURING HUMAN BRAIN DEVELOPMENT, SHOWING HOW THE 3D STRUCTURE OF CHROMATIN (DNA AND PROTEINS) PLAYS A CRITICAL ROLE. THE PUBLICLY AVAILABLE ONLINE RESOURCE WILL BE A VALUABLE TOOL SCIENTISTS CAN USE TO CONNECT GENETIC VARIANTS ASSOCIATED WITH THESE CONDITIONS TO THE GENES, CELLS, AND DEVELOPMENTAL PERIODS THAT ARE MOST SENSITIVE TO THEIR EFFECTS. THE STUDY WAS LED BY JOSEPH ECKER, PHD, AND PUBLISHED IN NATURE ON OCTOBER 9, 2024. THROUGH THE LOOKING GLASS: A CROSS-CHIRAL REACTION CHALLENGES OUR DEFINITION OF LIFE - JUST AS YOUR LEFT AND RIGHT HANDS EXIST AS MIRROR IMAGES OF EACH OTHER, MANY BIOLOGICAL MOLECULES HAVE THEIR OWN FORM OF LEFT- AND RIGHT-HANDEDNESS, CALLED CHIRALITY. ON EARTH, ALL RNA EXISTS IN A RIGHT-HANDED CHIRAL FORM. EVEN WHEN SCIENTISTS MAKE SYNTHETIC LEFT-HANDED VERSIONS, THE TWO GROUPS BEHAVE AS IF ON OPPOSITE SIDES OF A MIRROR, UNABLE TO INTERACT WITH EACH OTHER. BUT WHAT IF THEY COULD? USING SOPHISTICATED BIOENGINEERING TECHNIQUES, SALK SCIENTISTS ENGINEERED A CHEMICAL SYSTEM IN WHICH LEFT- AND RIGHT-HANDED VERSIONS OF AN RNA ENZYME COULD EFFECTIVELY "REACH THROUGH THE MIRROR REPLICATE EACH OTHER EXPONENTIALLY AND INDEFINITELY. THIS IS THE FIRST EVIDENCE OF A LIFELIKE CHEMICAL SYSTEM THAT OPERATES ON BOTH SIDES OF THE MIRROR OF CHIRALITY, CREATING THE OPPORTUNITY TO STUDY AN ENTIRELY NEW FORM OF BIOCHEMICAL EVOLUTION. THE ACHIEVEMENT COULD ALSO ADVANCE THE DEVELOPMENT OF CROSS-CHIRAL THERAPEUTICS, DIAGNOSTICS, AND OTHER BIOTECHNOLOGIES. THE STUDY WAS LED BY GERALD JOYCE, MD, PHD, AND PUBLISHED IN PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES ON OCTOBER 22, 2024. CHOLESTEROL IS NOT THE ONLY LIPID INVOLVED IN TRANS FAT-DRIVEN CARDIOVASCULAR DISEASE - HIGH CHOLESTEROL HAS LONG BEEN THE FOCUS OF MANY HEART HEALTH CAMPAIGNS DUE TO ITS ROLE IN FORMING ARTERY-CLOGGING PLAQUES THAT CAN LEAD TO STROKE, HEART ATTACK, OR ARTERIAL DISEASE. BUT NEW SALK RESEARCH REVEALED THAT ANOTHER CLASS OF LIPIDS, CALLED SPHINGOLIPIDS, CAN ALSO CONTRIBUTE TO ARTERIAL PLAQUES AND HEART DISEASE. WHEN THE TEAM TRACKED THE FLOW OF DIETARY FATS THROUGHOUT THE BODY, THEY FOUND THAT TRANS FATS WERE BEING METABOLIZED INTO SPHINGOLIPIDS, AND THIS DROVE THE LIVER TO SECRETE ARTERY-CLOGGING MOLECULES INTO THE BLOODSTREAM. THE DISCOVERY THAT SPHINGOLIPIDS-NOT JUST CHOLESTEROL-CAN DIRECTLY CONTRIBUTE TO ATHEROSCLEROTIC HEART DISEASE OPENS A WHOLE NEW SET OF MOLECULES AND PATHWAYS THAT COULD BE TARGETED WITH NEW DRUGS TO WARD OFF CARDIOVASCULAR DISEASE, HEART ATTACK, AND STROKE. THE STUDY WAS LED BY CHRISTIAN METALLO, PHD, AND PUBLISHED IN CELL METABOLISM ON NOVEMBER 14, 2024. |
| FORM 990, PART III, LINE 4A CONTINUED | NEUROSCIENTISTS DISCOVER HOW THE BRAIN SLOWS ANXIOUS BREATHING - HUMANS HAVE LONG USED SLOW BREATHING TO REGULATE EMOTIONS, AND, FOR THE FIRST TIME, SALK NEUROSCIENTISTS HAVE IDENTIFIED A SPECIFIC BRAIN CIRCUIT THAT MAKES THIS POSSIBLE. USING MICE, THE RESEARCHERS PINPOINTED A GROUP OF BRAIN CELLS IN THE FRONTAL CORTEX OF THE BRAIN THAT CONNECTS TO THE LOWER BRAINSTEM, WHERE VITAL ACTIONS LIKE BREATHING ARE CONTROLLED. THIS NEURAL PATHWAY ALLOWS US TO COORDINATE OUR BREATHING WITH OUR CURRENT BEHAVIORS AND EMOTIONAL STATE. NEW THERAPEUTICS DESIGNED TO TARGET THESE BRAIN CELLS COULD HELP PREVENT PANIC AND HYPERVENTILATION IN ANXIETY AND POST-TRAUMATIC STRESS DISORDERS. THE STUDY WAS LED BY SUNG HAN, PHD, AND PUBLISHED IN NATURE NEUROSCIENCE ON NOVEMBER 19, 2024. SUPERIOR PHOTOSYNTHESIS ABILITIES OF SOME PLANTS COULD HOLD KEY TO MORE RESILIENT CROPS - MORE THAN 3 BILLION YEARS AGO, ON AN EARTH ENTIRELY COVERED WITH WATER, PHOTOSYNTHESIS FIRST EVOLVED IN ANCIENT BACTERIA. THIS EVOLUTION WAS PUNCTUATED AROUND 30 MILLION YEARS AGO WITH THE EMERGENCE OF A NEWER, BETTER WAY TO PHOTOSYNTHESIZE CALLED C4 PHOTOSYNTHESIS. C4 PLANTS CAN THRIVE IN HOT, DRY CLIMATES AND ARE AMONG THE MOST PRODUCTIVE CROP SPECIES IN THE WORLD. HOWEVER, AROUND 95% OF PLANTS USE C3 PHOTOSYNTHESIS, A LESS EFFICIENT FORM THAT MAKES THEM MORE VULNERABLE TO DROUGHT AND HEAT. NOW, SALK AND UNIVERSITY OF CAMBRIDGE COLLABORATORS HAVE MADE A BREAKTHROUGH IN UNDERSTANDING THE EVOLUTION OF C4 PHOTOSYNTHESIS. THEIR FINDINGS MAY BE USED TO DRIVE C4 PHOTOSYNTHESIS IN IMPORTANT C3 CROPS LIKE RICE, WHEAT, AND SOYBEANS, MAKING THEM MORE PRODUCTIVE AND RESILIENT. THE STUDY WAS LED BY JOSEPH ECKER, PHD, AND PUBLISHED IN NATURE ON NOVEMBER 20, 2024. YOUR IMMUNE CELLS ARE WHAT THEY EAT - THE DECISION BETWEEN SCRAMBLED EGGS AND AN APPLE FOR BREAKFAST PROBABLY WON'T MAKE OR BREAK YOUR DAY, BUT FOR YOUR CELLS, A SIMILAR DECISION COULD DETERMINE THEIR ENTIRE IDENTITY. SALK RESEARCHERS FOUND THAT THE STATE OF THE IMMUNE SYSTEM'S T-CELLS COULD BE DETERMINED BY WHICH NUTRIENT THE CELL WAS METABOLIZING. SWITCHING FROM ACETATE TO CITRATE COULD SHIFT THE CELLS FROM AN ACTIVE, DISEASE-FIGHTING "EFFECTOR" STATE TO AN "EXHAUSTED" ONE. THE FINDINGS REVEAL HOW DIFFERENT NUTRIENTS CAN CHANGE A CELL'S GENE EXPRESSION, FUNCTION, AND IDENTITY. THEY ALSO SUGGEST THAT NEW THERAPIES COULD BE DESIGNED TO TARGET THESE NUTRIENT-DEPENDENT MECHANISMS TO HELP T CELLS REMAIN ACTIVE IN PATIENTS WITH CHRONIC DISEASES LIKE CANCER. THE STUDY WAS LED BY SUSAN KAECH, PHD, AND PUBLISHED IN SCIENCE ON DECEMBER 12, 2024. PLANT CELLS GAIN IMMUNE CAPABILITIES WHEN IT'S TIME TO FIGHT DISEASE - BECAUSE PLANT CELLS ARE IMMOBILE, EACH CELL IS FORCED TO MANAGE ITS OWN IMMUNITY ON TOP OF ITS MANY OTHER RESPONSIBILITIES. NEW SALK RESEARCH HELPS EXPLAIN HOW THESE MULTITASKING CELLS ACCOMPLISH IT ALL-DETECTING THREATS, RESPONDING TO THEM, AND WARNING OTHERS. WHEN PLANT CELLS ENCOUNTER A PATHOGEN, THEY ENTER A SPECIALIZED IMMUNE STATE AND TEMPORARILY BECOME PRIMARY IMMUNE RESPONDER (PRIMER) CELLS THAT ACT AS A HUB TO INITIATE THE IMMUNE RESPONSE. THESE PRIMER CELLS ARE ALSO SURROUNDED BY ANOTHER POPULATION OF CELLS, DEEMED BYSTANDER CELLS, WHICH SEEM TO BE IMPORTANT FOR TRANSMITTING THE IMMUNE RESPONSE THROUGHOUT THE PLANT. THE FINDINGS BRING US CLOSER TO UNDERSTANDING THE PLANT IMMUNE SYSTEM-AN INCREASINGLY IMPORTANT TASK AMID THE GROWING THREATS OF ANTIMICROBIAL RESISTANCE AND INFECTIOUS DISEASE. THE STUDY WAS LED BY JOSEPH ECKER, PHD, AND PUBLISHED IN NATURE ON JANUARY 8, 2025. TWO-IN-ONE ROOT ARMOR PROTECTS PLANTS FROM ENVIRONMENTAL STRESSORS AND CAPTURES EXCESS CARBON - TO COMPENSATE FOR THEIR INABILITY TO UP AND MOVE WHEN DANGER STRIKES, MANY PLANTS HAVE EVOLVED DIFFERENT WAYS TO PROTECT THEMSELVES, SUCH AS BUILDING AN ARMOR CALLED THE PERIDERM AROUND THEIR BODY AND ROOTS. SALK RESEARCHERS HAVE DEBUTED THE FIRST COMPREHENSIVE GENE EXPRESSION ATLAS OF THE PLANT PERIDERM AT THE SINGLE-CELL LEVEL. THIS INCLUDES IMPORTANT INSIGHTS INTO PHELLEM CELLS, WHICH ARE RICH IN SUBERIN-A MOLECULE THAT HELPS CAPTURE AND STORE EXCESS CARBON DIOXIDE FROM THE ATMOSPHERE. SCIENTISTS CAN NOW USE THIS INFORMATION TO STIMULATE PERIDERM GROWTH IN PLANTS FACING ENVIRONMENTAL STRESS, OR BOOST PHELLEM CELL GENES TO PRODUCE PLANTS WITH ENHANCED CARBON-CAPTURING ABILITIES-A CENTRAL GOAL OF SALK'S HARNESSING PLANTS INITIATIVE. THE STUDY WAS LED BY WOLFGANG BUSCH, PHD, AND PUBLISHED IN DEVELOPMENTAL CELL ON JANUARY 9, 2025. PUTTING A LID ON EXCESS CHOLESTEROL TO HALT BLADDER CANCER CELL GROWTH - BLADDER CANCER IS THE FOURTH MOST COMMON CANCER IN MEN, AND, LIKE ALL CANCERS, IT DEVELOPS WHEN ABNORMAL CELLS START TO MULTIPLY OUT OF CONTROL. SALK CANCER BIOLOGISTS HAVE DISCOVERED THAT PIN1, A PROTEIN FIRST DISCOVERED IN THE LAB OF TONY HUNTER, PHD, IN 1996, IS A MAJOR DRIVER OF BLADDER CANCER. THEY REVEALED THAT IT WORKS BY TRIGGERING THE SYNTHESIS OF CHOLESTEROL-A LIPID THAT CANCER CELLS USE AS FUEL TO GROW. THE RESEARCHERS DEVELOPED AN EFFECTIVE TWO-DRUG TREATMENT REGIMEN THAT HALTED TUMOR GROWTH IN MICE: SULFOPIN, AN EXPERIMENTAL PIN1 INHIBITOR, AND SIMVASTATIN, A STATIN THAT IS ALREADY COMMONLY USED IN HUMANS TO LOWER CHOLESTEROL LEVELS AND REDUCE THE RISK OF HEART DISEASE. THE STUDY WAS LED BY HUNTER AND PUBLISHED IN CANCER DISCOVERY, A JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, ON JANUARY 14, 2025. BILE ACIDS EXACERBATE LIVER CANCER, DIETARY SUPPLEMENT MAY OFFER RELIEF - IMMUNOTHERAPY HAS MADE AN INCREDIBLE IMPACT ON TREATING CANCERS OF THE LUNG, KIDNEY, AND SKIN-BUT FOR LIVER CANCER, THE TREATMENT HAS BEEN MUCH LESS EFFECTIVE. TO UNDERSTAND WHY, SALK RESEARCHERS TOOK A CLOSER LOOK AT HOW THE IMMUNE SYSTEM AND LIVER INTERACT. THEY DISCOVERED THAT CERTAIN BILE ACIDS IN THE LIVER WERE AFFECTING THE ACTIVITY OF CANCER-FIGHTING IMMUNE CELLS CALLED T-CELLS. BUT WHILE MANY OF THESE BILE ACIDS WERE IMPAIRING T-CELL FUNCTION, ONE SPECIFIC BILE ACID, CALLED URSODEOXYCHOLIC ACID (UDCA), WAS ACTUALLY BOOSTING THEIR ACTIVITY. AND WHEN MICE WERE GIVEN A UDCA DIETARY SUPPLEMENT, IT WAS ENOUGH TO CONTROL LIVER TUMOR GROWTH. SINCE UDCA IS ALREADY AVAILABLE AS A GENERIC MEDICATION, THE RESEARCHERS ARE HOPEFUL THAT IT COULD BE INCORPORATED INTO LIVER CANCER TREATMENTS TO MAKE IMMUNOTHERAPY MORE EFFECTIVE FOR THESE PATIENTS. THE STUDY WAS LED BY SUSAN KAECH, PHD, AND PUBLISHED IN SCIENCE ON JANUARY 9, 2025. BOOSTING THIS MOLECULE COULD HELP RETAIN MUSCLE WHILE LOSING FAT - WEIGHT LOSS DOESN'T DISCRIMINATE BETWEEN FAT AND MUSCLE. PATIENTS USING GLP-1 DRUGS CAN EXPERIENCE RAPID AND SUBSTANTIAL MUSCLE LOSS, ACCOUNTING FOR AS MUCH AS 40 PERCENT OF THEIR TOTAL WEIGHT LOSS. SALK RESEARCHERS DISCOVERED THAT A PROTEIN CALLED BCL6 IS KEY TO MAINTAINING HEALTHY MUSCLE MASS. THE EXPERIMENTS SHOWED THAT FASTING LED TO LOWER BCL6 LEVELS AND REDUCED MUSCLE MASS AND STRENGTH IN MICE, BUT INCREASING BCL6 SUCCESSFULLY REVERSED THESE LOSSES. THE RESEARCHERS SUGGEST THAT PAIRING GLP-1 MEDICATIONS WITH A BCL6-BOOSTING DRUG MAY HELP COUNTERACT UNWANTED MUSCLE LOSS. SIMILAR THERAPIES COULD ALSO BE USED TO TREAT OTHER POPULATIONS PRONE TO MUSCLE LOSS, SUCH AS OLDER ADULTS AND PATIENTS WITH SYSTEMIC DISEASES LIKE SEPSIS OR CANCER. THE STUDY WAS LED BY RONALD EVANS, PHD, AND PUBLISHED IN PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES ON JANUARY 22, 2025. NEW STUDY EXPLAINS HOW ANTIDEPRESSANTS CAN PROTECT AGAINST INFECTIONS AND SEPSIS - ANTIDEPRESSANTS LIKE PROZAC ARE COMMONLY PRESCRIBED TO TREAT MENTAL HEALTH DISORDERS, BUT NEW RESEARCH SUGGESTS THEY COULD ALSO PROTECT AGAINST LIFE-THREATENING SEPSIS AND SERIOUS INFECTIONS. SALK SCIENTISTS HAVE UNCOVERED HOW THESE DRUGS ARE ABLE TO REGULATE THE IMMUNE SYSTEM AND DEFEND AGAINST INFECTIOUS DISEASE. THEY FOUND THAT PROZAC INCREASED LEVELS OF AN IMMUNE SYSTEM MOLECULE CALLED INTERLEUKIN-10 IN MICE, WHICH LED TO REDUCED INFLAMMATION AND PREVENTED SEPSIS-INDUCED HEART FAILURE. THESE INSIGHTS COULD LEAD TO A NEW GENERATION OF LIFESAVING MEDICATIONS AND ENHANCE GLOBAL PREPAREDNESS FOR FUTURE PANDEMICS. THE STUDY WAS LED BY JANELLE AYRES, PHD, AND PUBLISHED IN SCIENCE ADVANCES ON FEBRUARY 14, 2025. PEPTIDE IMITATION IS THE SINCEREST FORM OF PLANT FLATTERY - FERTILIZER PRODUCTION CONSUMES MASSIVE AMOUNTS OF ENERGY, AND ITS USE POLLUTES THE WATER, AIR, AND LAND. SALK PLANT BIOLOGISTS ARE PROPOSING A NEW SOLUTION TO HELP KICK THIS UNSUSTAINABLE FERTILIZER HABIT. IN THEIR NEW STUDY, THE RESEARCHERS IDENTIFIED A KEY MOLECULE PRODUCED BY PLANT ROOTS, A SMALL PEPTIDE CALLED CLE16 THAT ENCOURAGES PLANTS AND BENEFICIAL SOIL FUNGI TO INTERACT WITH EACH OTHER. THEY SAY BOOSTING THIS SYMBIOTIC RELATIONSHIP, IN WHICH THE FUNGI PROVIDE MINERAL NUTRIENTS TO THE PLANTS THROUGH CLE16 SUPPLEMENTATION, COULD BE A MORE NATURAL AND SUSTAINABLE WAY TO ENCOURAGE CROP GROWTH WITHOUT THE USE OF HARMFUL ARTIFICIAL FERTILIZERS. THE STUDY WAS LED BY LENA MUELLER, PHD, AND PUBLISHED IN PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES ON APRIL 14, 2025. |
| FORM 990, PART III, LINE 4A CONTINUED | ESTROGEN-RELATED RECEPTORS COULD BE KEY TO TREATING METABOLIC AND MUSCULAR DISORDERS - ACROSS THE BODY, TINY BEAN-SHAPED STRUCTURES CALLED MITOCHONDRIA TURN THE FOOD WE EAT INTO USABLE ENERGY. THIS CELLULAR-LEVEL METABOLISM IS ESPECIALLY IMPORTANT IN MUSCLE CELLS, WHICH REQUIRE A LOT OF FUEL TO POWER OUR MOVEMENT. MITOCHONDRIAL DYSFUNCTION IS DIFFICULT TO TREAT, BUT RECENT SALK FINDINGS SHOW THAT A GROUP OF PROTEINS CALLED ESTROGEN-RELATED RECEPTORS COULD BE A NEW AND EFFECTIVE THERAPEUTIC TARGET. THE SCIENTISTS DISCOVERED THAT ESTROGEN-RELATED RECEPTORS PLAY AN IMPORTANT ROLE IN MUSCLE CELL METABOLISM-ESPECIALLY DURING EXERCISE. DEVELOPING A DRUG TO BOOST ESTROGEN-RELATED RECEPTORS COULD BE A POWERFUL WAY TO RESTORE ENERGY SUPPLIES IN PEOPLE WITH METABOLIC DISORDERS, SUCH AS MUSCULAR DYSTROPHY. THE STUDY WAS LED BY RONALD EVANS, PHD, AND PUBLISHED IN PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES ON MAY 12, 2025. ACTION! PROTEINS CRITICAL TO HEALTHY BRAIN DEVELOPMENT CAPTURED ON FILM - OUR CELLS RELY ON MICROSCOPIC HIGHWAYS AND SPECIALIZED PROTEIN VEHICLES TO MOVE EVERYTHING-FROM POSITIONING ORGANELLES TO CARTING PROTEIN INSTRUCTIONS TO DISPOSING OF CELLULAR GARBAGE. THESE HIGHWAYS (CALLED MICROTUBULES) AND VEHICLES (CALLED MOTOR PROTEINS) ARE INDISPENSABLE TO CELLULAR FUNCTION AND SURVIVAL. USING ADVANCED MODERN IMAGING TECHNIQUES, SALK RESEARCHERS MADE A MOLECULAR MOVIE OF THE MOTOR PROTEIN DYNEIN BEING TURNED ON BY ITS SMALL PARTNER PROTEIN LIS1. THE FINDINGS PAVE THE WAY FOR NEW THERAPEUTICS THAT RESTORE LIS1 AND DYNEIN FUNCTION-A CRUCIAL TASK, SINCE THEIR DYSFUNCTION CAN LEAD TO SEVERE DEVELOPMENTAL AND NEUROLOGICAL DISORDERS. THE STUDY WAS LED BY AGNIESZKA KENDRICK, PHD, AND PUBLISHED IN NATURE STRUCTURAL & MOLECULAR BIOLOGY ON MAY 23, 2025. CANNABIS PANGENOME REVEALS POTENTIAL FOR MEDICINAL AND INDUSTRIAL USE - CANNABIS HAS BEEN A GLOBALLY IMPORTANT CROP FOR MILLENNIA, SERVING AS A CORNERSTONE OF HUMAN CIVILIZATION BY PROVIDING SEED OIL, TEXTILES, AND FOOD FOR OVER 10,000 YEARS. TODAY, CANNABIS REMAINS AN UNDERSTUDIED AND UNDERUTILIZED RESOURCE, BUT US BILLS PASSED IN 2014 AND 2018 HAVE RE-ENERGIZED CANNABIS CROP DEVELOPMENT FOR MEDICINAL, GRAIN, AND FIBER APPLICATIONS. SALK PLANT BIOLOGISTS HAVE CREATED THE MOST COMPREHENSIVE, HIGH-QUALITY, AND DETAILED GENETIC ATLAS OF CANNABIS TO DATE. THE TEAM ANALYZED 193 DIFFERENT CANNABIS GENOMES (ENTIRE SETS OF GENETIC INFORMATION), REVEALING AN UNPRECEDENTED DIVERSITY, COMPLEXITY, AND UNTAPPED OPPORTUNITY WITHIN THIS FOUNDATIONAL AGRICULTURAL SPECIES. THEIR FINDINGS SET THE STAGE FOR TRANSFORMATIVE ADVANCES IN CANNABIS-BASED AGRICULTURE, MEDICINE, AND INDUSTRY. THE STUDY WAS LED BY TODD MICHAEL, PHD, AND PUBLISHED IN NATURE ON MAY 28, 2025. |
| Software ID: | 24020961 |
| Software Version: | 2024v5.1 |